Al's Comment:

 SurVaxM is an experimental vaccine for the treatment of brain tumors. Early results from a small trial were recently reported   Of 63 patients with newly diagnosed Glioblastoma, the median overall survival was 25.9 months from the first dose of the vaccine, which was probably 3-4 months from diagnosis.  Our guest speaker is Michael J. Ciesielski, PhD, CEO of Mimivax. This should be of interest to all people dealing with brain tumors.

Posted on: 07/18/2023

Announcement: Webinar tonight (Tuesday 7/18/23) on SurVaxM Vaccine for Brain Tumor Treatment   

Join us for an insightful webinar discussing the SurVaxM vaccine, an experimental therapy for the treatment of brain tumors currently undergoing clinical trials. The preliminary results have been promising, offering hope for patients and their families.
We are excited to invite you to our upcoming webinar, scheduled for TONIGHT,  Tuesday, July 18, 2023, at 7 pm Eastern Time. The session is open to all, with a special emphasis on patients and families seeking information and support. There is no charge to attend, and registration is not required. Simply visit approximately 5 minutes before the event begins to join the session.
During the webinar, we will explore the latest developments and insights regarding the SurVaxM vaccine, and address any questions or concerns you may have.
We believe that knowledge empowers individuals and communities, and we welcome everyone to join us for this informative event. Together, let us work towards advancing medical understanding and improving the lives of those affected by brain tumors.
Please mark your calendars for the SurVaxM Vaccine Webinar and spread the word to those who might benefit from this invaluable discussion. We look forward to your participation!


Click HERE to return to brain tumor news headlines.

Our privacy / cookie policy has changed.
Click HERE to read it!